Helix BioPharma Corp. Completes Data Review of First Four Cohorts of Its Phase I/II Clinical Study for Lung Cancer Drug Candidate L-DOS47 - Seite 3

The total number of patients to be enrolled in the study will ultimately depend on how many ascending dose levels are required to reach the maximum tolerated dose (MTD); however, the Company currently anticipates that the study will enroll less than the estimated maximum of 48 patients in Phase I, as previously reported. Helix expects that twenty patients will be enrolled in the Phase II portion of the study at the MTD dose determined in Phase I. Study patients will be male or female, at least 18 years of age, with histologically confirmed non-small cell lung cancer. Patients will have an Eastern Cooperative Oncology Group ("ECOG") performance status of 0 - 2 at the screening visit for this study, and will have at least one site of measurable disease per RECIST v1.1.

The study is currently being conducted at four Polish centres; The Maria Sklodowska-Curie Memorial Cancer Centre & Institute of Oncology, The Military Medical Institute, The National Tuberculosis and Lung Diseases Research Institute and The Mazovian Centre of Pulmonary Diseases and Tuberculosis. As previously reported, the Company is actively recruiting new centers to participate in order to expand this study.

About Helix BioPharma Corp.

Helix BioPharma Corp. is a biopharmaceutical company specializing in the field of cancer therapy. The company is actively developing innovative products for the prevention and treatment of cancer based on its proprietary technologies. Helix's product development initiatives include its novel L-DOS47 new drug candidate and its Topical Interferon Alpha-2b. Helix is currently listed on the TSX and FSE under the symbol "HBP".

Forward-Looking Statements and Risks and Uncertainties

This news release contains certain forward-looking statements and information (collectively, "forward-looking statements") within the meaning of applicable Canadian securities laws, including, without limitation, those relating to the total number of patients to be enrolled in the Polish Phase I/II clinical study, the anticipated timelines for completion of such enrolment, the conduct of a further, formal analysis of available data. Forward-looking statements, which may be identified by words including, without limitation, "will", "may", "anticipates", "expects", and other similar expressions, are intended to provide information about management's current plans and expectations regarding the conduct of the clinical study.